The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.
Immunocore, a UK-based bispecific immunotherapy developer with roots at University of Oxford, has filed to raise up to $100m in an initial public offering.
Immunocore is developing T-cell engaging receptors (TCR) antibody treatments for cancer, infectious and autoimmune diseases.
The company was set up by biotechnology firm Medigene in 2008 to commercialise aspects of Avidex technology, the latter having been spun out of Oxford in 1999. A sister company, Adaptimmune, was formed concurrently to market other…
